Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)

 Full screen view
Filter results: >>>>
Cell line Drug name Experimental replicate Timepoint Curve type (GR values) Curve type (relative cell counts) Experiment name Number of concentrations Cell doublings (DMSO control) GR50 GRmax GR_AOC GEC50 GRinf Hill slope (GR values) R-squared sigmoid fit (GR values) P-value sigmoid fit (GR values) R-squared flat fit (GR values) IC50 Emax AUC EC50 Einf Hill slope (relative cell counts) R-squared sigmoid fit (relative cell counts) P-value sigmoid fit (relative cell counts) R-squared flat fit (relative cell counts)
BT-549 BX-912 3 72
sigmoid
sigmoid
BT549 BX-912 0 3 72
 8 1.728
1.0
0.335
0.109
0.758
0.332
3.91
0.993
2.87e-07
NA
2.46
0.497
0.916
0.73
0.496
3.92
0.992
6.03e-07
NA
BT-549 Alpelisib 2 72
sigmoid
sigmoid
BT549 alpelisib 0 2 72
 8 1.927
Inf
0.832
0.0409
4.24
0.663
0.548
0.706
0.0254
NA
Inf
0.844
0.962
4.26
0.686
0.542
0.696
0.0282
NA
BT-549 CAL-101 1 72
sigmoid
sigmoid
BT549 idelalisib 0 1 72
 8 1.791
Inf
0.836
0.041
4.8
0.605
0.778
0.924
0.00044
NA
Inf
0.858
0.964
4.79
0.659
0.767
0.92
0.000518
NA
BT-549 CAL-101 2 72
sigmoid
sigmoid
BT549 idelalisib 0 2 72
 8 1.975
Inf
0.792
0.0561
4.65
0.526
0.693
0.933
0.000307
NA
43.0
0.805
0.946
43.0
0.0
0.548
0.932
0.000314
NA
BT-549 CAL-101 3 72
sigmoid
sigmoid
BT549 idelalisib 0 3 72
 8 1.770
43.0
0.79
0.0687
320.0
-0.664
0.421
0.862
0.00261
NA
118.0
0.822
0.941
118.0
0.0
0.425
0.854
0.00309
NA
BT-549 Everolimus 1 72
sigmoid
sigmoid
BT549 everolimus 0 1 72
 8 1.772
5.64
0.503
0.444
1e-05
0.367
0.1
0.911
0.000706
NA
437200.0
0.603
0.641
0.000146
0.444
0.1
0.858
0.00286
NA
BT-549 Everolimus 3 72
sigmoid
flat
BT549 everolimus 0 3 72
 8 1.587
59.5
0.533
0.425
1e-05
0.395
0.1
0.702
0.0264
NA
Inf
0.656
0.685
0.0
0.656
0.01
0.48
0.141
0.685